Mosunetuzumab: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 11, p. 1229, doi. 10.1007/s40265-022-01749-5
- By:
- Publication type:
- Article
Works matching IS 00126667 AND DT 2022 AND VI 82 AND IP 11
Results: 9
1
2
Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy.
- Published in:
- Drugs, 2022, v. 82, n. 11, p. 1165, doi. 10.1007/s40265-022-01755-7
- By:
- Publication type:
- Article
3
Correction to: Mavacamten: First Approval.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
4
New Developments in Glucagon Treatment for Hypoglycemia.
- Published in:
- Drugs, 2022, v. 82, n. 11, p. 1179, doi. 10.1007/s40265-022-01754-8
- By:
- Publication type:
- Article
5
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries.
- Published in:
- Drugs, 2022, v. 82, n. 11, p. 1193, doi. 10.1007/s40265-022-01751-x
- By:
- Publication type:
- Article
6
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets.
- Published in:
- Drugs, 2022, v. 82, n. 11, p. 1151, doi. 10.1007/s40265-022-01750-y
- By:
- Publication type:
- Article
7
Tapinarof Cream 1%: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 11, p. 1221, doi. 10.1007/s40265-022-01748-6
- By:
- Publication type:
- Article
8
Tirzepatide: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 11, p. 1213, doi. 10.1007/s40265-022-01746-8
- By:
- Publication type:
- Article
9
Desidustat: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 11, p. 1207, doi. 10.1007/s40265-022-01744-w
- By:
- Publication type:
- Article